The Clinical Service Provider

EPS Co., Ltd.

2007

Business Report
October 1, 2006 〜 September 30, 2007

Our Services

We support international research and development in Asia
In 1999 we became the first Japanese CRO to

have numerous medical professionals and expert

establish a subsidiary in China and have since

staff well versed in clinical trial regulations whostarted planning, regulatory submissions andprovide high quality clinical trial services in China

project management of clinical trials in Asia. We

and Southeast Asia. We currently support local

Profile of the President & CEO of EPS Co., Ltd.
Yan Hao was born in Jiangsu Province, China in 1962. He enrolled in
University of Tianjin in 1979, and then, came to Japan in 1981, as a Chinese
governmental scholar. After completion of a master course majoring in
Computer Science at University of Yamanashi, he advanced to Ph.D. Course
at the University of Tokyo, to major in Biometrics and Medical Informatics.
In 1991 when he was still a graduate student at the University of Tokyo,
Yan established EPS Co., Ltd. as one of the few CRO (Contract Research
Organizations) in Japan at that time. EPS Co., Ltd. made a successful IPO
on the JASDAQ market, Tokyo, in 2001, becoming the first public CRO
company in Japan. Also, EPS Listed a stock on the Second Section of theTokyo Stock Exchange in 2004,and Listed a stock on the First Section of the
EPS Co., Ltd. President & CEO
YAN HAO

2

Tokyo Stock Exchange in 2006.

submissions and clinical investigations for
submission in Japan and clinical research for EBM

Major Services

through partnerships with EPS China Co., Ltd.
(Shanghai, Beijing, Guangzhou), EPS Singapore(Ever Progressing System Pte Ltd.), and otherpartners.
Through partnership with leading world CROs
based in Europe and the U.S., we also support
global development of domestic and overseas
pharmaceutical companies. Based on our clinical• Regulatory consultation/development ofclinical trials• Support for development of documents forregulatory submission and regulatory
application on behalf of clientele• Development of trial-related documents
such as protocol and CRFs

development know-how and experience cultivated• Drug randomization

as a CRO, in the future we intend to reinforce• Monitoringsuch consultation capabilities as licensing and• Data management

marketing strategies, with a view toward business• Statistical analysis

expansion to pharmaceutical companies and bio-

• Medical writing

venture companies in Asia, especially new• Various marketing surveys and marketingbusinesses in product development utilizing

promotion consultation

Chinese market characteristics, in order to further
enrich our services.

3

Our Services

EPS Overseas Network

Germany

Europe Business Partner

BeijingUSA
Shanghai

Guangzhou

Tie-up CRO

Korea Japan
TaiwanSingapore

South Africa

Tie-up CRO

Countries and Regions to which We can Respond:
China, Taiwan, Korea, Singapore, Malaysia, US, South Africa

Our Contract Experience Includes Achievements in:[Therapeutic Areas]
Cardiovascular drugs, ophthalmic drugs, metabolic drugs,
CNS drugs, PNS drugs, allergic drugs, externaldermatological drugs, tumor drugs, antibiotics,
chemotherapies (antivirus agents), digestive organ drugs,
revitalizers, etc.
4[Services]
Strategic consultation, regulatory application, clinical trial
planning and monitoring, statistical consultation, data
management, statistical analysis, medical writing,
distribution channel exploration, various investigations,etc.

Advantage of EPS
1. The number of staff totals over 100
employees with medical and pharmaceuticalcareer backgrounds and experience in DM
and statistical analysis.

2. Our company is one of the largest CROs in
China and, with its unique web-based caseenrollment and data management systems,
is capable of large-scale clinical trials
intended for EBM.

3. Local staff can speak both Japanese andEnglish. They can give detailed responses
appropriate to client requests.

4. Utilizing our extensive network with local
administration and medical sites, we realize
efficient clinical trials.

5

EPS GroupAim of the group: Establishment of an efficient system to provide a full service for drug development
The core business of the EPS Group is with CRO services. We aim from all aspects to establish a system that can fully support pharmaceutical companies with entire
drug development, from preclinical trials through regulatory submission. In synergy with our group company, we also provide services such as SMO, staffing, and thepreclinical study business.
Our targets include the promotion and expansion of existing businesses, the further development of overseas activities, the exploration of new businesses, as well as
improving service quality for customers worldwide.

Outline of Business:Global Contract Research Organization
Office:Tokyo

Outline of Business:Software & CRO Coordination
Office:Tokyo
URL:http://www.e-trial.co.jp/

Office:Beijing / Shanghai / Guangzhou
URL:http://www.epscn.com/

Outline of Business:CSO
Office:Tokyo
URL:http://www.c-medicalnet.co.jp/

Office:Singapore

Outline of Business:SMO
Office:Hokkaido / Tohoku / Tokyo / Chubu / Kansai /Chugoku / Kyusyu
URL:http://www.epmint.co.jp/

Office:Korea
Outline of Business:Pre-clinical Study Agent
Office:Tokyo / Chicago (US) / Makati (Philippines)
URL:http://www.lsg.co.jp

Outline of Business:CRO / Temporary Staffing
Office:Tokyo / Osaka
URL:http://www.epmate.co.jp/

6Outline of Business:Software Development
Office:Tokyo / Beijing
URL:http://www.allrightsoft.co.jp/

Process ofDevelopment

MedicalInstitution

Laboratory /University

Bio
VenturePharmaceutical
Company

Medical Device
Company

Foods
Company

System Integrator

Bio Venture

Drug
Discovery

Pre-clinical Study BusinessPre-clinicalStudy

Site Management Organization

Software Development

Contact Research Organization

Clinical
Trial

Submission /Approval /Marketing

CRO / Temporary Staffing

IT CROInternational

PostMarketing
Surveillance7

Review of Business Performance
Management results for the current term

booming in spite of the shortage of IT engineers.

Though the Japanese economy in this consolidated fiscal
year has causes for concern such as the trends in US

The CRO business is mainly operated by EPS Co., Ltd.

economy and crude oil prices, and raised interest, theOur monitoring business is developing favorably in both

corporate earnings still maintain strength on upward trends

development stage trials and post-marketing clinical trials,

in capital investment and personal consumption, leading towith focus on performance of existing projects, acquisitiona mild increase in business. In such circumstances, theof new projects, and trials of drugs for cancers, diabetes

CRO (Contract Research Organization) business to whichand central nerves, under the control of the Clinical

EPS Co., Ltd belongs to and the SMO (Site Management

Development Division. In the medical device development

Organization) business in which EP-Mint Co., Ltd., ourbusiness, the business assignment in the previous

consolidated subsidiary, is operating are growing throughconsolidated fiscal year contributed to the significant

restructuring, with the pre-clinical study business in which

growth in sales compared to the previous consolidated

LSG Corporation is developing its business maintaining afiscal year.

steady performance. Also, the software development

In the services of registration, progress management,

business in which All Right Software Inc. is operating isdata management and statistics analysis businesses, theChange of Business PerformanceNon-consolidated■Consolidated

Net Sales(UNIT:JPY MILLION)

9,479

10,891
17,980
0

1,793
1,587

Sep-06

15,257

Sep-07

1,142

Sep-0513,004

Sep-06

8(UNIT:JPY MILLION)
7,896

Sep-05

Non-consolidated■Consolidated

Operating Income

2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000

1,958
1,983

Sep-07

2,980
0

400

800

1,200

1,600

2,000

2,400

2,800

3,200

Biometrics Division is also doing well in both performance

investment securities is reported as extraordinary loss.

of the existing projects and acquisition of new projects. In

However, the sales of each division rose steadily, posting

this consolidated fiscal year, the operating rate has

increases in both profit and revenue compared to theincreased due to the development of the system toprevious consolidated fiscal year due to increased sales,

respond to contract projects flexibly, increase in cases ofenhanced operating rate associated with more efficient

existing projects and acquisition of new projects. We areservices, and cost saving efforts.

pushing hard to win orders for medical writing andAs for our consolidated subsidiaries, e-Trial Co., Ltd, whichpharmacovigilance businesses, whose sales has grown

was established in the previous consolidated fiscal year tocompared to the previous consolidated fiscal year.

contract EDC-based clinical trials in Japan, concentrates on

The Clinical Coordination Center which plans and offers

winning new contracts, improving its performance steadily.

services for new projects engages in performance of

EP-Mate Co., Ltd, which dispatches staff to pharmaceutical

existing projects and acquisition of new projects, recording

companies (dispatched CRO services), is also improving its

a significant increase in its sales compared to the previous

results favorably.

consolidated fiscal year.

EPMedical Co., Ltd, which dispatches MRs (CSO

On the non-consolidated basis, the valuation loss onservices), has increased the number of MRs to be dispatched

Non-consolidated■Consolidated

Net Income(UNIT:JPY MILLION)(UNIT:JPY)
813

Sep-05980

Sep-06

1,079
1,384
200

400

600

800

1,000

13,07011,171

Sep-06

1,079

Sep-07

9,433

Sep-051,126

0

Non-consolidated■Consolidated

Net Income per Share

1,200

1,400

12,30012,074

Sep-07

15,485
0

4,000

8,000

12,00016,0009

Review of Business Performancethrough acquisition of new projects, though it has incurredprior investment expenses.
The overseas CRO business was succeeded by EPS
International Co., Ltd. (Voting right ratio 100%) which wascontract projects there.
EPLUS Co., Ltd. has become a 100% subsidiarythrough the transfer of proprietary right from Sosei Group
Corporation in June 2007.

established in April 2007 through the company split to

As a result, the consolidated sales of the CRO businessprovide rapid, professional and appropriate services toreached 12,254 million yen (increase of 18.9% comparedcustomers in response to the increasing demand for clinicalto the previous consolidated fiscal year) and thetrials in overseas (especially Asia) with each passing year.

consolidated operating profit was 2,157 million yen

The subsidiary is promoting with overseas subsidiaries the(increase of 25.8% on the same basis), leading to a steadydevelopment of the system to correspond to the increase

increase of profit and revenue.

in demand for CRO businesses associated with clinical
trials across the countries.
In this overseas subsidiary group, EPS China Co., Ltd.,The SMO business is operated by EP-Mint Co., Ltd.
EP-Mint Co., Ltd, while continuing to engage in the CRC

though ending of the large-scale project contracted inbusiness, is developing the internal organization after the

China, its profit and revenue are on the rise compared tomerger with focus on the site support business for clinicalthe previous consolidated fiscal year. Ever Progressing

trial bureaus in cooperation with local medical

System Pte. Ltd. has reduced its profit and revenue

organizations, making available the management systemcompared to the previous consolidated fiscal year in spite

according to branch with the result of enhanced sales andof its efforts to acquire new customers independently. ADM

cost management.

Korea Inc. has joined the Group since this consolidated

Sogo Mediplus Co., Ltd., an associate subject to equity

fiscal year and is operating contract clinical trial services inmethod established on November 1, 2005 to promote the

Korea (an associate subject to equity method, located inpartnership with Sogo Clinical Holdings Co., Ltd (Voting

Seoul, South Korea; capitalized at 153 million won

right ratio of EP-Mint: 20%, the same of Sogo Clinical(approximately 19 million yen); voting right ratio: 35.0%).

Holdings: 80%), has terminated its role and completed

The associate is developing the system for joint contract

liquidation on July 31, 2007.

projects in Korea. EPS International Co., Ltd. established its

As a result, the consolidated sales of the SMO businessTaiwan Branch in July 2007 to develop the system for joint

was 3,375 million yen (increase of 13.2% compared to the10previous consolidated fiscal year) with the consolidatedof 35.7% compared to the previous consolidated fiscal year)

operating profit of 643 million yen (increase of 624.8% on

with the consolidated operating profit of 89 million yen

the same basis), achieving a significant increase in profit(increase of 33.5 % on the same basis), leading to aand revenue.

significant increase in profit and revenue.

The pre-clinical study business is operated by the LSG

The above-mentioned consolidated sales and operating

Corporation Group.

profits by segment include those for the internal transactions

LSG Corporation has been an uphill struggle under the

between segments. Therefore, after deducting them, theinfluence of the group reorganization of overseas pre-clinicalcurrent consolidated sales was 17,980 million yen (increase

study contractors in the previous consolidated fiscal year,of 17.8% compared to the previous consolidated fiscal year)

though the agent service for new overseas pre-clinicalwith the consolidated operating profit of 2,980 million yen

study contractors is looking up.

(increase of 52.2% on the same basis) and the consolidated

As a result, the consolidated sales of the pre-clinicalordinary profit of 3,042 million yen (increase of 53.7% on the

study business reached 1,259 million yen (increase of 5.2%

same basis), leading to a significant increase in profit andcompared to the previous consolidated fiscal year) with therevenue. Despite the extraordinary loss of 345 million yen due

consolidated operating profit of 77 million yen (increase of

to the valuation loss on investment securities, the current

7.0% on the same basis), leading to enhanced profit andconsolidated net profit was 1,384 million yen (increase ofrevenue.

28.3% on the same basis) resulting in enhanced profit andrevenue.

The software development business is operated by the
All Right Software Inc. Group.
All Right Software Inc. continues to promote the businessusing Chinese IT engineers, and the contract SE service forthe backbone system for financial institutions and major
companies is growing significantly.
As a result, the consolidated sales of the softwaredevelopment business reached 1,250 million yen (increase11

Financial Information
CONSOLIDATED BALANCE SHEETS(IN THOUSANDS, JPY)SEPTEMBER 30,
2006

SEPTEMBER 30,
2007

ASSETSSEPTEMBER 30,
2007

Accounts payable

182,795

201,903213,200

214,300

375,282

1,063,181

LIABILITIESCURRENT ASSETSCURRENT LIABILITIESCash and cash equivalents

3,792,223

5,260,080

Notes and accounts receivable

3,607,909

4,126,574−

200,012Current portion of long-term debt

Inventories

339,862437,696

Income taxes payable

Deferred tax assets

252,655

391,347

Provision for bonuses

Pocket through expense

145,275

243,601

Investment securities

422,541649,722

Others

1,171,583

1,861,952

2,365,403

3,991,058

Long-term debt

670,000

405,700

Provision for employee's retirement benefits

227,604

258,448

Provision for director's retirement benefits

130,499

155,023

Others264,222

296,927

Allowance for doubtful accounts△ 1,411△ 1,523

Total current liabilities

Total current assets

8,400,737

10,954,717

LONG-TERM LIABILITIESFIXED ASSETS
Tangible Assets ;Leasehold improvements

344,453

383,711

Accumulated depreciation△ 180,245△ 200,747

203,274

238,233△ 131,006△ 143,660

Furniture and fixtures
Accumulated depreciation
Others
Accumulated depreciation

133,053

175,931△ 54,723△ 77,075

314,805

376,393

Goodwill

315,666

247,666

Others67,993

97,410Total intangible assets

383,660

345,077

Total property and equipment

Deferred tax liabilities

4,258

2,518

Others

5,825

14,204

Total long-term liabilities

1,038,188

835,895

TOTAL LIABILITIES

3,403,591

4,826,953

Common stock

1,875,251

1,875,251

Additional paid-in capital

1,825,298

1,825,298

Retained earnings

4,180,774

5,205,599

Common stock for treasury△ 322,080△ 322,080

89,59066,076NET ASSETS

Intangible Assets ;Investments and other assets ;1,275,110

1,074,612

Long-term loans receivable

45,61747,268Deposits

666,687

681,724

Time deposits and banking arrangements
other than cash equivalents

500,000

500,000

Deferred gain on hedges

Deferred tax assets

188,142

320,997

Foreign currency translation adjustments

OthersTotal shareholders' equity

Investment securities

12

SEPTEMBER 30,
2006

198,961

246,456

Allowance for doubtful accounts−△ 10,000

Total investments and other assets

2,874,519

2,861,059

Unrealized gain on
available-for-sale securities

Minority interests

Total fixed assets

3,572,985

3,582,530

TOTAL NET ASSETSTOTAL ASSETS

11,973,723

14,537,247

TOTAL LIABILITIES AND NET ASSETS−

485

40,552

67,262

7,689,386

8,717,892

880,745

992,401

8,570,131

9,710,293

11,973,723

14,537,247

CONSOLIDATED STATEMENTS OF INCOME(IN THOUSANDS, JPY)

FOR THE YEAR ENDED FOR THE YEAR ENDEDSEPTEMBER 30, 2006 SEPTEMBER 30, 2007

FOR THE YEAR ENDED FOR THE YEAR ENDEDSEPTEMBER 30, 2006 SEPTEMBER 30, 2007

NET SALES

15,257,985

17,980,875

Compensation for office removal−

61,080COST OF SALES

10,892,074

12,046,656

Gross profit

4,365,911

5,934,218

Gain on decrease of sharesin associated company

4,001

−

Loss on sales and disposalof property and equipment(14,743)(61,266)

Loss on devaluation of investment
in securities

SELLING, GENERAL AND
ADMINISTRATIVE EXPENSES

2,407,205

2,953,488

Operating income

1,958,705

2,980,730(87,593)(345,918)Interest income

27,69038,069Impairment loss

(3,635)−Interest expenses(20,682)(15,771)

Loss on devaluation of software(28,083)−

Gain on cancellation of life insurance

10,91916,746

Provision for doubtful accounts−(10,000)

Service fee income

3,317

6,056

Others- net(9,830)(2,860)Gain on consumption tax filing

7,988

14,618Other income (expenses)-net(118,093)(258,533)

Incentive on re-investment in overseas subsidiaries

7,711

−

Income before income taxes and minority interests

1,840,612

2,722,197
1,409,739

OTHER INCOME (EXPENSES)INCOME TAXES

Payment to the Association for
employment of persons with disabilities(3,050)(5,350)Current

782,199

Foreign exchange loss

(3,884)−

Deferred(89,728)(255,795)

Equity in losses of associated companies(9,213)(5,708)

Total

692,470

1,153,944

Gain on sales of property and equipment

995

584

Gain on sale of investments in securities−

51,186MINORITY INTERESTSNET INCOME

69,055

183,865

1,079,085

1,384,387

CONSOLIDATED STATEMENT OF CHANGES IN NET ASSETS(IN THOUSANDS, JPY)

Attributable to equity holders of the company
Commonstock

Additional
paid-in capital

1,875,251

1,825,298

Evaluation and translation adjustment
Total
Unrealized gain on Deferred gain Foreign currency Total evaluation Shareholders'available-for-saletranslationand translation
equityon hedges
securities
adjustments
adjustments

Minority
interest

Total
net assets

880,745

8,570,131

Common stock
for treasury

Sub total

4,180,774 △ 322,080

7,559,243

Cash dividends△ 357,592△ 357,592△ 357,592△ 357,592

Net income

1,384,387

1,384,387

1,384,387

1,384,387

Others△ 1,970△ 1,970△ 1,970△ 1,970

Balance at 30 September 2006

Retainedearnings

89,590−40,552130,142

7,689,386

Changes during the period

Net increase/decrease invaluation, translation adjustment
and minority interest
Total changes during the period−−

Balance at 30 September 2007

1,875,251

1,825,298△ 23,514

485

26,709

3,681

3,681

111,655

115,337−

1,024,824△ 23,514

485

26,7093,681

1,028,505

111,655

1,140,161

5,205,599 △ 322,080

8,584,068

66,076

485

67,262

133,823

8,717,892

992,401

9,710,293

1,024,824

13

Financial Information

CONSOLIDATED STATEMENTS OF CASH FLOWS(IN THOUSANDS, JPY)

FOR THE YEAR ENDED FOR THE YEAR ENDEDSEPTEMBER 30, 2006 SEPTEMBER 30, 2007
OPERATING ACTIVITIES:
Income before income taxes andminority interests

INVESTING ACTIVITIES:
1,840,612

2,722,197

Adjustments to reconcile income
before income taxes and minority
interests to net cash provided byoperating activities:
Depreciation and amortization

133,848

109,352

Disbursements for purchase of
tangible fixed assets△ 146,885△ 178,665

Disbursements for purchase ofintangible fixed assets△ 25,686△ 37,714

Payment for purchase ofinvestments securities△ 477,290△ 439,793

Proceeds from sales of investments
securities−

95,186

Payment for deposit for rent office and others△ 82,086△ 197,211

Impairment loss

3,635

−

Amortization of Goodwill

15,802

61,983

Increase in provision for bonuses

50,769226,430

Increase in allowance for retirement
benefits for employees

22,05830,844

Increase in allowance for retirement
benefits for directors

8,163

24,524

Net cash provided by (used in)investing activities△ 28,890△ 39,569

Interest and dividends income
Interest expense
Gain on sale of investments in securities
Loss on devaluation of investments
in securities
Loss on sales and disposal of property
and equipment

Decrease in accounts receivable-trade(△Increase)
Increase in inventories
Increase in pocket through expense

Payment for acquisition of goodwill△ 340,000−

Others , Net△ 21,192

31,592△ 1,139,038△ 605,009△ 43,678−

15,771

Proceeds from borrowing long-term debt

1,092,000−

Disbursements for repayment of long-term debt

△ 295,624△ 263,200

Proceeds from issuance of bonds

1,997,743−

Disbursements for redemption of bonds△ 900,000−

Disbursement for acquisition of treasury stock△ 1,041−

87,593
14,743345,918
61,266

Proceeds from issuance of common
stock to minority stock holders
92,792△ 511,143△ 109,861△ 71,298△ 45,255△ 97,874

24,351

16,734
667,652

Others , Net

43,109△ 104,848

Subtotal

2,357,062

3,406,754

Net cash provided by (used in)operating activities△ 52,289△ 51,186

182,905

Income taxes paid

173,885△ 45,897−

Increase in other current liabilities

Interest paid−

Payment for insurance reserve fund

20,682

Increase in accounts payable -trade

Interest and dividends received

Collection of deposits for rent office and others

FINANCING ACTIVITIES:
Disbursements for repayments of finance leases

Changes in operating assets and liabilities:

14

FOR THE YEAR ENDED FOR THE YEAR ENDEDSEPTEMBER 30, 2006 SEPTEMBER 30, 2007

14,055−

Dividends paid

△ 231,444△ 357,397

Dividends paid for minority stock holders△ 18,794△ 15,813

Others , Net△ 4,018△ 1,553

Net cash provided by (used in)financing activities

1,609,198△ 637,964

EFFECT OF EXCHANGE DIFFERENCE
ON CASH & CASH EQUIVALENTS

17,722

13,178NET INCREASE IN CASH AND CASH
EQUIVALENTS

1,845,361

1,467,856

1,946,862

3,792,223

3,792,223

5,260,080

27,986

37,797△ 20,682△ 15,749△ 1,006,887△ 731,149

BEGINNING OF BALANCE, CASH AND
CASH EQUIVALENTS

2,697,652

ENDING OF BALANCE, CASH AND
CASH EQUIVALENTS

1,357,478

Stock Information(As of September 30, 2007)

Current Situation of SharesClassification of Shareholders

Authorized stocks

324,000

Share of common stock issued

90,400

Other resident companies 18.96%

Number of shareholders

4,091

17,138 shares
29 persons

Principal Shareholders

Common stock for treasury
Number of Percentage
share held of total(%)

Name of shareholders
Hao Yan

17,654

19.52

Y & G Limited

16,76018.53

The Bank of New York for GCM Client
Accounts (E) ISG

5,029

5.56

Sumitomo Life Insurance Company

2,700

2.98

Japan Trustee Services Bank, Ltd., T.

2,527

2.79

Nomura Trust and Banking Co., Ltd., Inv. T.

2,128

2.35

The Master Trust Bank of Japan, Ltd.

1,839

2.03

Tokio Marine & Nichido Fire Insurance Co., Ltd.

1,620

1.79

The Chase Manhattan Bank N. A., London SL
Omnibus Account

1,567

1.73

Mellon Bank Treaty Clients Omnibus

1,533

1.69

1.10%
1,002 shares

Securities company 1.30%

Personal/Others

1,178 shares
20 persons

45.15%
40,817 shares
3,950 persons

Finance institution 15.50%
14,014 shares
30 persons

Nonresident 17.98%
16,250 shares
62 persons

Note: Self-name is not included in the number of shareholders.

Members of the Board and Statutory Auditors
President & CEO

Mr. Yan Hao

Executive Directors

Mr. Koichi Jingu

Executive Directors

Mr. Tatsuhiko Ichiki

Directors

Mr. Tomohiro Tominaga

Directors

Mr. Yasuharu Tamai

Statutory Auditors

Mr. Kozo Okunaga

Statutory Auditors

Mr. Junichi Ishikawa

Statutory Auditors

Mr. Koichi Shibuya(As of September 30, 2007)15

Company Profile
Corporate Name : EPS Co., Ltd.
President & CEO : Yan Hao
Establishment: May 1991

Capital: ¥1875.25 Million

Main Services: CRO business and System Development

E-Mail: info@eps.co.jp

URL: http://www.eps.co.jp

Locations: Center Office
Tsuruya Bldg., 2-23 Shimomiyabi-cho, Shinjuku-ku,
Tokyo 1620822
TEL. +81-3-5684-7801
Annex.1
2-3-19 Koraku, Bunkyo-ku, Tokyo 1120004
TEL. +81-3-5684-7797
Annex.2
Iidabashi MF Bldg., 1-1 Shinogawa-cho, Shinjuku-ku,
Tokyo 1620814
TEL. +81-3-5804-7639
Osaka Branch
Nissei Shin-osaka Bldg., 3-4-30 Miyahara,
Yodogawa-ku, Osaka 5320003
TEL. +81-6-4807-7107
Nagoya BranchHoriuchi Bldg., 3-25-9 Meieki, Nakamura-ku, Nagoya4500002
TEL. +81-52-581-8887

Cert no. SA-COC-1210

The Clinical Service Provider

EPS Co., Ltd.

Printed in Japan using soy-based inks on FSC-certified paper.
This document uses a waterless printing method that generates noharmful waste liquid.